AHA 2023 Potential Dapagliflozin Benefit Post-MI Is Not a 'Mandate' A registry trial of SGLT-2 inhibition in low-risk patients after an MI showed some benefit in preventing future events, but a larger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results